Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GHSG-AFM13 Phase 2 in Relapsed/Refractory Hodgkin Lymphoma
2014-004036-19Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Jan 2015
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acimtamig in Hodgkin lymphoma (HL), sponsored by University of Cologne. Primary endpoint: Objective response rate after one 8-week cycle of AFM13. Started Jan 2015; status: completed.
02
Drugs
acimtamig
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2014-004036-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004036-19.